us6047491013_102224.txt

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No:  1)

Mirum Pharmaceuticals, Inc
--------------------------------------------------------
(Name of Issuer)

 Common Stock
--------------------------------------------------------
(Title of Class of Securities)

604749101
--------------------------------------------------------
(CUSIP Number)

September 30, 2024
--------------------------------------------------------
(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to
which this Schedule is filed:

[X] Rule 13d-1(b)
[ ] Rule 13d-1(c)
[ ] Rule 13d-1(d)


*The remainder of this cover page shall be filled out
for a reporting person's initial filing on this form with
respect to the subject class of securities, and for any
subsequent amendment containing information which
would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover
page shall not be deemed to be "filed" for the purpose
of Section 18 of the Securities Exchange Act of 1934
("Act") or otherwise subject to the liabilities of that
section of the Act but shall be subject to all other
provisions of the Act (however, see the Notes).





CUSIP No.   604749101

(1)Names of reporting persons. BlackRock, Inc.


(2) Check the appropriate box if a member of a group
(a) [  ]
(b) [X]


(3) SEC use only

(4) Citizenship or place of organization

Delaware

Number of shares beneficially owned by each reporting person with:

(5) Sole voting power

 0

(6) Shared voting power

 0

(7) Sole dispositive power

 3368157

(8) Shared dispositive power

 0

(9) Aggregate amount beneficially owned by each reporting person

 3368157

(10) Check if the aggregate amount in Row (9) excludes certain shares

(11) Percent of class represented by amount in Row 9

 7.1%

(12) Type of reporting person

HC





Item 1.

Item 1(a) Name of issuer:
-----------------------------------------------------------------------

Mirum Pharmaceuticals, Inc

Item 1(b) Address of issuer's principal executive offices:
-----------------------------------------------------------------------

989 EAST HILLSDALE BOULEVARD, SUITE 300
foster city CA 94404


Item 2.


2(a) Name of person filing:
----------------------------------------------------------------------
BlackRock, Inc.


2(b) Address or principal business office or, if none, residence:
-----------------------------------------------------------------------
BlackRock, Inc.
50 Hudson Yards
New York, NY 10001


2(c) Citizenship:
--------------------------------------------------------------------
 See Item 4 of Cover Page


2(d) Title of class of securities:
-------------------------------------------------------------------

 Common Stock

2(e) CUSIP No.:
See Cover Page






Item 3.

If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c),
check whether the person filing is a:
[ ] Broker or dealer registered under Section 15 of the Act;
[ ] Bank as defined in Section 3(a)(6) of the Act;
[ ] Insurance company as defined in Section 3(a)(19) of the Act;
[ ] Investment company registered under Section 8 of the
Investment Company Act of 1940;
[ ] An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
[ ] An employee benefit plan or endowment fund in accordance with
            Rule 13d-1(b)(1)(ii)(F);
[X] A parent holding company or control person in accordance with
            Rule 13d-1(b)(1)(ii)(G);
[ ] A savings associations as defined in Section 3(b) of the Federal
            Deposit Insurance Act (12 U.S.C. 1813);
[ ] A church plan that is excluded from the definition of an
            investment company under section 3(c)(14) of the Investment Company
            Act of 1940;
[ ] A non-U.S. institution in accordance with
            Rule 240.13d-1(b)(1)(ii)(J);
[ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing
            as a non-U.S. institution in accordance with
            Rule 240.13d-1(b)(1)(ii)(J), please specify the type of
            institution:


Item 4. Ownership*

Provide the following information regarding the aggregate number
and percentage of the class of securities of the issuer identified in Item 1.


Amount beneficially owned:

  3368157

Percent of class

7.1%

Number of shares as to which such person has:

Sole power to vote or to direct the vote

  0

Shared power to vote or to direct the vote

  0

Sole power to dispose or to direct the disposition of

  3368157

Shared power to dispose or to direct the disposition of

  0









Item 5.

Ownership of 5 Percent or Less of a Class. If this statement is being
filed to report the fact that as of the date hereof the reporting person
has ceased to be the beneficial owner of more than 5 percent of the
class of securities, check the following [  ].


Item 6. Ownership of More than 5 Percent on Behalf of Another Person

  If any other person is known to have the right to receive or the power
  to direct the receipt of dividends from, or the proceeds from the sale
  of, such securities, a statement to that effect should be included in
  response to this item and, if such interest relates to more than 5 percent
  of the class, such person should be identified. A listing of the
  shareholders of an investment company registered under the Investment
  Company Act of 1940 or the beneficiaries of employee benefit plan,
  pension fund or endowment fund is not required.

  Various persons have the right to receive or the power to direct
   the receipt of dividends from, or the proceeds from the sale of
   the common stock of
   Mirum Pharmaceuticals, Inc.
   No one person's interest in the common stock of
   Mirum Pharmaceuticals, Inc
   is more than five percent of the total outstanding common shares.

Item 7. Identification and Classification of the Subsidiary Which
Acquired the Security Being Reported on by the Parent Holding
Company or Control Person.


See Exhibit A


Item 8. Identification and Classification of Members of the Group


If a group has filed this schedule pursuant to Rule 13d-1(b)(ii)(J),
so indicate under Item 3(j) and attach an exhibit stating the identity
and Item 3 classification of each member of the group. If a group
has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d),
attach an exhibit stating the identity of each member of the group.


Item 9. Notice of Dissolution of Group

Notice of dissolution of a group may be furnished as an exhibit
stating the date of the dissolution and that all further filings with
respect to transactions in the security reported on will be filed,
if required, by members of the group, in their individual capacity.

See Item 5.

Item 10. Certifications
By signing below I certify that, to the best of my knowledge and
belief, the securities referred to above were acquired and are
held in the ordinary course of business and were not acquired
and are not held for the purpose of or with the effect of changing
or influencing the control of the issuer of the securities and were
not acquired and are not held in connection with or as a participant
in any transaction having that purpose or effect.

* In accordance with SEC Release
 No. 34-39538 (January 12, 1998), this Schedule 13G reflects the
 securities beneficially owned, or deemed to be beneficially owned,
 by BlackRock, Inc. It does not include securities, if any,
 beneficially owned by certain business units whose ownership
 of securities is disaggregated from that of BlackRock, Inc.
 in accordance with such release.

Signature.

After reasonable inquiry and to the best of my knowledge and
belief, I certify that the information set forth in this statement
is true, complete and correct.


Dated: October 22, 2024
BlackRock, Inc.

Signature:  Spencer Fleming



-------------------------------------------

Name/Title Attorney-In-Fact


The original statement shall be signed by each person on whose
behalf the statement is filed or his authorized representative.
If the statement is signed on behalf of a person by his authorized
representative other than an executive officer or general partner
of the filing person, evidence of the representative's authority to
sign on behalf of such person shall be filed with the statement,
provided, however, that a power of attorney for this purpose
which is already on file with the Commission may be incorporated
by reference. The name and any title of each person who
signs the statement shall be typed or printed beneath his signature.



Attention: Intentional misstatements or omissions of fact constitute
Federal criminal violations (see 18 U.S.C. 1001).


Exhibit A



Subsidiary


 BlackRock Advisors, LLC
 Aperio Group, LLC
 BlackRock Asset Management Canada Limited
 BlackRock Investment Management (Australia) Limited
 BlackRock Fund Advisors
 BlackRock Asset Management Ireland Limited
 BlackRock Institutional Trust Company, National Association
 BlackRock Financial Management, Inc.
 BlackRock Fund Managers Ltd
 BlackRock Japan Co., Ltd.
 BlackRock Asset Management Schweiz AG
 BlackRock Investment Management, LLC



*Entity beneficially owns 5% or greater of the outstanding
shares of the security class being reported on this
Schedule 13G.


Exhibit B


POWER OF ATTORNEY

The undersigned, BlackRock, Inc., a corporation duly organized under the laws
of the State of Delaware, United States (the "Company"), does hereby make,
constitute and appoint each of Eric Andruczyk, Richard Cundiff,
R. Andrew Dickson, III, Spencer Fleming, Daniel Goldmintz, Laura Hildner,
Elizabeth Kogut, David Maryles, Christopher Meade, Una Neary, Charles Park,
Daniel Riemer, David Rothenberg and Brenda Schulz, acting severally, as its
true and lawful attorneys-in-fact, for the purpose of, from time to
time, executing, in its name and on its behalf and on behalf of its direct
and indirect subsidiaries, any and all documents, certificates, instruments,
statements, filings, agreements and amendments (collectively, "documents")
determined by such person to be necessary or appropriate to comply with
ownership or control-person reporting requirements imposed by any
United States or non-United States governmental or regulatory authority,
including, without limitation, Schedules 13D and 13G and Forms 3, 4, 5, 13F
and 13H and any amendments to any of the foregoing as may be required to be
filed with the Securities and Exchange Commission, and delivering, furnishing
or filing any such documents with the appropriate governmental or regulatory
authority or other person, and giving and granting to each such
attorney-in-fact full power and authority to do and perform any and every act
and thing whatsoever requisite, necessary or proper to be done in the exercise
of any of the rights and powers herein granted, as fully and to all intents
and purposes as the Company and/or its direct and indirect subsidiaries, as
applicable, might or could do if personally present by one of its authorized
signatories, hereby ratifying and confirming all that said attorney-in-fact
shall lawfully do or cause to be done by virtue hereof. Any such determination
by an attorney-in-fact named herein shall be conclusively evidenced by such
person's execution, delivery, furnishing or filing of the applicable document.

This power of attorney shall expressly revoke the power of attorney dated 2nd
day of January, 2019 in respect of the subject matter hereof, shall be valid
from the date hereof and shall remain in full force and effect until either
revoked in writing by the Company, or, in respect of any attorney-in-fact
named herein, until such person ceases to be an employee of the Company or
one of its affiliates.

IN WITNESS WHEREOF, the undersigned has caused this power of attorney to be
executed as of this 30th day of April, 2023.

BlackRock, Inc.


By: /s/ R. Andrew Dickson, III
Name:  R. Andrew Dickson, III
Title: Corporate Secretary